Supernus Pharmaceuticals Inc (SUPN) Expected to Post Quarterly Sales of $88.02 Million

Brokerages forecast that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will report $88.02 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $92.17 million and the lowest estimate coming in at $84.15 million. Supernus Pharmaceuticals reported sales of $62.37 million during the same quarter last year, which indicates a positive year-over-year growth rate of 41.1%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year sales of $88.02 million for the current fiscal year, with estimates ranging from $294.60 million to $305.98 million. For the next fiscal year, analysts anticipate that the company will post sales of $393.97 million per share, with estimates ranging from $385.13 million to $404.56 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The firm had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. The firm’s revenue was up 41.5% on a year-over-year basis.

SUPN has been the subject of a number of research analyst reports. Piper Jaffray Companies reissued a “hold” rating and issued a $41.00 target price on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. Cantor Fitzgerald reissued a “buy” rating and issued a $49.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. FBR & Co initiated coverage on Supernus Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $53.00 target price for the company. Cowen set a $50.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $61.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $49.90.

In related news, VP Victor Vaughn sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total transaction of $630,600.00. Following the sale, the vice president now owns 24,344 shares in the company, valued at $1,023,421.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $44.98, for a total value of $899,600.00. Following the sale, the vice president now owns 32,500 shares in the company, valued at approximately $1,461,850. The disclosure for this sale can be found here. Insiders have sold 145,750 shares of company stock valued at $6,173,173 over the last ninety days. 6.70% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pinebridge Investments L.P. raised its holdings in Supernus Pharmaceuticals by 1.3% during the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after acquiring an additional 86 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Supernus Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after acquiring an additional 128 shares in the last quarter. CS Mckee LP raised its holdings in Supernus Pharmaceuticals by 0.5% during the second quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock worth $1,812,000 after acquiring an additional 200 shares in the last quarter. Advisor Group Inc. raised its holdings in Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 410 shares in the last quarter. Finally, Suntrust Banks Inc. raised its holdings in Supernus Pharmaceuticals by 2.5% during the second quarter. Suntrust Banks Inc. now owns 20,402 shares of the specialty pharmaceutical company’s stock worth $878,000 after acquiring an additional 489 shares in the last quarter. Institutional investors and hedge funds own 98.22% of the company’s stock.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $46.90 on Friday. Supernus Pharmaceuticals has a 52 week low of $23.10 and a 52 week high of $50.04. The stock has a market capitalization of $2,400.00, a PE ratio of 42.64 and a beta of 1.17.

TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/20/supernus-pharmaceuticals-inc-supn-expected-to-post-quarterly-sales-of-88-02-million-2.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply